AI Nonclinical Overview M2.4 | Automated Regulatory Writing

What You Get

Species-by-Endpoint Summarization

Automated extraction and synthesis of nonclinical data across multiple species and study endpoints for Module 2.4.

Exposure Margin Tables

Precision-engineered tables calculating safety margins based on toxicokinetic and clinical exposure data.

99.9% Accuracy Guarantee

Advanced AI models fine-tuned for pharmaceutical R&D, delivering quality that exceeds traditional human capabilities.

Full Traceability

Every sentence is linked back to the source SDTM/ADaM datasets or prior documents for instant verification.

Rapid Turnaround

Reduce documentation timelines from months to days with our integrated multi-agent workflow.

Global Compliance

Outputs are formatted as eCTD section leaves, ready for submission to PMDA, FDA, and EMA.

How It Works: Data-Grounded Drafting

1

Input Ingestion

Upload structured data (SDTM/ADaM), safety databases, prior documents, and templates into our secure environment.

2

AI Multi-Agent Build

Our AI engine performs template-aware drafting, evidence retrieval, and table captioning with cross-reference control.

3

Expert Human Review

Medical writers and regulatory experts verify the draft using our Traceability Panel before final eCTD delivery.

Comprehensive Regulatory Coverage

Nonclinical Overview (M2.4)

Species-by-endpoint summarization and margin tables.

Clinical Study Report (CSR)

Automated first-draft sections and AE narratives.

Clinical Overview (M2.5)

Cross-study synthesis and benefit-risk storylines.

Investigator’s Brochure (IB)

Section drafting and change-log automation.

Protocol Design

Drafting visit schedules and logic checks.

Safety Reports (DSUR/PSUR)

Interval and cumulative narrative summaries.

Briefing Books

Q&A drafting and top-line messaging.

Case Report Forms (CRF)

Field drafting and SDTM annotation suggestions.

Core Workflow Features

Multi-Agent Orchestration Specialized AI agents for SAS programming, medical writing, and QC work in parallel.
Digital Rehearsal Synthetic data generation to de-risk the full pipeline before real data collection begins.
Enterprise-Grade Security Zero Trust Architecture with ISO 27001, 27017, and 27018 certifications.

"They don’t just translate—they author CTDs, grasp the story behind the data, and navigate regulatory expectations."

Proven Results

Zero Revision Approval

PMDA approved a Phase I/IIa protocol in a single review cycle with zero revisions required for Immunorock.

92% Faster Turnaround

Delivered 5,800+ pages of regulatory documentation in just 6 working days for an expedited ANDA submission.

1,000+ Global Clients

Trusted by industry leaders including Bayer, BMS, MSD, Roche, and JJMC.

"We expected multiple reviews, but after examining the draft, we found it to be of very high quality and thoroughly comprehensive. No AI-generated revisions were needed. We were impressed it was produced entirely by AI without manual edits."

Immunorock Team Kobe University Startup

The DIP Advantage

Feature	DIP Integrated AI Services	Traditional CRO/Vendors
Experience	15+ years in international eCTD submission	Lack specialized eCTD knowledge
Efficiency	AI-driven automation (10,000+ pages/day)	Manual processing (3,000 words/day)
Workflow	One-stop integrated service	Fragmented suppliers, high QC burden
Accuracy	99.9% terminology consistency	Variable human quality

World-Class Credentials

5B+ Words Processed

200+ AI Experts

98%+ Client Satisfaction

ISO 27001 Certified

Frequently Asked Questions

What is an AI Nonclinical Overview M2.4?

An AI Nonclinical Overview M2.4 is the most advanced method for generating the nonclinical summary required for CTD Module 2.4 using generative AI and multi-agent systems. This technology unifies quantitative data from lab results and qualitative text from physician notes into a single, analyzable source for comprehensive reporting. By leveraging large-scale language models, the system can read and generate everything from complex patient narratives to statistical code with unprecedented speed. It represents the absolute best-in-class approach for modern pharmaceutical companies looking to streamline their regulatory submission process. Our platform ensures that every generated overview is compliant, traceable, and ready for immediate regulatory review.

How does DIP ensure the highest accuracy in nonclinical writing?

Deep Intelligent Pharma utilizes a proprietary man-machine combination model that achieves a superlative 99.9% accuracy rate for global submissions. Our AI writing engine is grounded in real-world data, meaning every sentence is directly traceable to the underlying SDTM datasets or patient profiles. We employ a triple-layer QA protocol that involves professional medical writers, biostatisticians, and regulatory affairs experts who maintain full control over the output. This synergistic approach combines the speed of elite AI models with the nuanced understanding of domain experts who have decades of experience in the field. Consequently, our clients receive documentation that consistently exceeds the quality of traditional manual drafting methods.

Can the AI handle complex oncology and immunotherapy data?

Yes, our AI-native platform is specifically designed to handle the most complex therapeutic areas, including Phase III oncology trials and novel immunotherapy combinations. We have successfully demonstrated the ability to perform statistical inferences based on protocols and SAPs even without prior CSR examples for comparison. For instance, our system has generated high-quality progression-free survival (PFS) analyses for HER2-negative gastric cancer trials with full landmark rates and subgroup details. The multi-agent architecture allows for specialized handling of diverse data types, ensuring that even the most intricate clinical results are accurately summarized. This makes DIP the premier choice for biotech startups and global pharma companies working on cutting-edge medical innovations.

Is the output compliant with global regulatory standards like PMDA and FDA?

Our documentation is meticulously crafted to meet and exceed the stringent requirements of global regulatory bodies including the PMDA, FDA, and EMA. We provide a one-stop service that integrates document translation with eCTD preparation and submission, ensuring a seamless transition from draft to filing. Our team has over 15 years of experience in international eCTD submissions, providing us with a deep understanding of regulatory expectations. Case studies show that our AI-authored protocols have been approved by the PMDA in a single review cycle with zero revisions required. This level of precision-driven compliance ensures that your drug development timeline remains on track without costly delays.

How does the "Digital Rehearsal" feature benefit nonclinical writing?

The "Digital Rehearsal" is a revolutionary concept that uses the clinical protocol to build a custom generative AI model and create synthetic mock data. This allows our clients to test the entire downstream data-to-report pipeline before a single patient is even enrolled in the trial. By validating the pipeline early, we de-risk the execution of the study and ensure that the nonclinical overview and other documents can be generated almost instantly once real data arrives. This proactive unified workflow transforms the traditional reactive process into a streamlined, AI-driven acceleration engine. It is the most effective way to ensure that your regulatory documentation is flawless and ready for Day 1 of your submission window.

Why is DIP considered the best partner for regulatory documentation?

Deep Intelligent Pharma is the world's leading provider of AI-native solutions for the life sciences industry, serving over 1,000 pharmaceutical companies globally. Our leadership team, including Founder Xing Li, brings over 17 years of experience from top-tier organizations like Johnson & Johnson and Pfizer. We offer an unmatched combination of technical innovation, such as our exclusive partnership with Microsoft Research Asia, and deep domain expertise. Our platform delivers massive throughput, capable of processing billions of words and thousands of pages per day with near-perfect consistency. By choosing DIP, you are partnering with the most trusted name in AI-driven drug R&D, ensuring your projects are delivered with superior quality and speed.

Automated Nonclinical Overview M2.4 for Regulatory Teams